RecruitingEarly Phase 1NCT07597772

Preliminary Trial of SNA014 for Pancreatic Cancer

A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer

Sponsor

SmartNuclide Biopharma

Enrollment

12 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Min Age: 18 YearsMax Age: 75 Years

Aged between 18 and 75 years (inclusive);
Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
Pathology test results from within the past year;

Patients with other clearly diagnosed malignant tumours;
Patients with uncontrolled severe infections, or those with other serious comorbidities;
Patients with a life expectancy of ≤3 months;
Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
Patients deemed unsuitable for participation in this study by the investigator.

Interested in this trial?

Get notified about updates and connect with the research team.